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Treatment for outpatients with comorbid schizophrenia and 
substance use disorders: a review 
 
Abstract  
Aims: This review provides evidence of which interventions need to be part of effective 
outpatient integrated treatment for patients with comorbid schizophrenia and substance use 
disorders. Methods: A total of 14 randomized controlled trials were included. Effect sizes are 
provided to assess the magnitude of the treatments’ efficacy. Results: Despite the studies’ 
heterogeneity, we can conclude that certain programs (e.g., Behavioral Treatment for 
Substance Abuse in Schizophrenia) and specific interventions (e.g., motivational 
interviewing, family interventions) seem to be effective. Moreover, programs integrating 
multiple interventions are more likely to be positively related to better outcomes than single 
interventions. Finally, the lack of difference between effect sizes of assertive community 
treatment compared to case management suggests that a lower caseload is not necessary 
for positive treatment outcomes. Conclusion: Integrated treatment seems advantageous, 
although effect sizes are mostly modest. More homogeneous and qualitative sound studies 
are needed. 
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1. Introduction 
Schizophrenia is a severe psychiatric disorder that can cause long-standing impairments in 
several life domains. The overall outcome of schizophrenia is notably heterogeneous. 
Several clinical characteristics are related to better or worse outcomes [1], with concurrent 
substance use disorder (SUD) being consistently associated with worse outcome. In fact, 
patients with schizophrenia and SUD, when compared to patients with a single diagnosis, 
have more severe (positive) symptoms, less treatment compliance, more re-hospitalizations, 
a higher degree of homelessness, and more legal, medical and social problems [2-7]. These 
factors are associated with worse overall outcome and higher treatment and societal costs. 
A sizeable portion of patients with schizophrenia suffers from comorbid SUD. Indeed, 
both high lifetime (47%; [8]) and current (27%; [9]) prevalence of SUD has been reported by 
epidemiological studies. However, these dual disorder (DD) patients do not fit in the 
traditional treatment systems, where addiction and mental health care do considerably differ 
[10] so that health care professionals continuingly demand for specialized treatment settings 
for these difficult to treat patients. As a consequence, the last 2 decades have seen the 
development of the paradigm of integrated treatment (IT), i.e. treatment programs in which 
addiction and mental health interventions are offered at the same time and by the same 
team. However, the interpretation of the effectiveness of these programs is ambiguous and 
particularly complicated by the great variety of different interventions, the heterogeneity of 
the patient samples, and the lack of consistent reports of effect sizes of the outcome studies.   
First, apart from the target population (i.e., dual disorder patients), there are very few 
similarities between different integrated programs. They vary greatly in terms of the number 
and type of interventions they include, the degree of comprehensiveness, duration and 
intensity of treatment, and the setting in which they are offered. Interventions that have often 
been implemented in IT are motivational interviewing (MI), cognitive behavioral therapy 
(CBT), relapse prevention (RP), case management (CM), assertive community treatment 
(ACT), and family interventions (FI). MI is aimed at increasing the motivation for change by 
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emphasizing personal choice, responsibility and consciousness about the risks and 
advantages of continued substance use. CBT is focused at learning specific behavioral skills 
to cope with stress and certain problems and to accomplish well-set goals. RP is a form of 
CBT specifically focused on preventing relapse. CM is an intervention in which a treating 
agency coordinates the care of a patient by ensuring access to different types of 
interventions. ACT (often considered to be a subtype of CM) not only coordinates care, but 
also offers mobile assertive outreaching. ACT consists of several components: care in the 
community, assertive engagement, high intensity, small caseload, continuous responsibility 
and availability, consistent multidisciplinary team, team approach, and cooperation with the 
patient’s support network [11]. The content of FI is very diverse, but it is often aimed at 
increasing the family’s knowledge about DD and ameliorating communication between the 
family and the team and/or patient. Finally, there recently has been an increase in attention 
for contingency management (CoM) in this patient group. In CoM, adaptive behavior (e.g., 
negative urine sample) is rewarded by positive consequences. 
In addition to the heterogeinity of treatment programs, interpretation of the 
effectiveness of IT is hampered by the great heterogeineity of patients included in the 
different outcome-studies. Most outcome-studies include mixed patient samples, with only a 
relatively small proportion of patients with schizophrenia and SUD. For example, the review 
Brunette, Mueser, and Drake [12] concluded that residential IT is more effective than 
treatment as usual (TAU). Furthermore, Drake, O’Neil and Wallach [13] also conclude that IT 
seems advantageous. However, both reviews reflect studies with very heterogeneous patient 
populations (different diagnostic groups), making it difficult to transfer the results to the 
specificities of patients with schizophrenia [14]. An additional problem within the existing 
outcome studies is that the effect sizes of IT are only fragmentarily (e.g., only SUD or 
psychiatric outcome variables) or not at all reported, making it difficult to interpret the 
findings. Furthermore, most studies do not assign patients randomly to the treatment 
conditions. 
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Finally, it needs to be taken into account that most of the existing IT programs are 
offered within the context of outpatient services and rarely in residential treatment settings. 
This is in accordance with the current mental healthcare developments supported by the 
World Health Organization (WHO) and other leading healthcare organizations, putting a 
focus on outpatient, community based treatment organization for patients with severe mental 
illnesses [15-16]. The focus in mental health care is currently shifting from traditional 
residential treatment centers to outpatient, community-based settings in which the patient is 
being treated in an integrative way. Given these (societal) evolutions, the fact that most 
studies focus on outpatient programs, and the need for homogeneity when comparing the 
effectiveness between studies, we focus in this review specifically on outpatient programs. 
Although the concept of IT is widely acclaimed and has been well received from the 
perspective of patient’s treatment satisfaction [17], the evidence remains mainly expert 
driven. In addition, there is still a lack of consensus about which specific interventions should 
be included in an IT approach. This review provides much-needed information on the efficacy 
of outpatient treatment for patients with schizophrenia and comorbid SUD by offering an 
overview of available randomized controlled trials (RCTs) on this topic and reporting 
treatment effect sizes, which will help in comparing studies and coming to a consensus 
regarding specific interventions that need to be included in an IT program. 
 
2. Materials and methods 
2.1. Study sources and selection 
Internet databases (PsycInfo, Pubmed, and Web of Knowledge) were searched for RCTs 
with specific treatment interventions for patients suffering from comorbid schizophrenia and 
SUD (limited to the English language) until December 2012. Additionally, cross references of 
the selected articles were checked and retrieved. Articles were selected for review when they 
included an RCT with (a) a sample consisting of participants with schizophrenia/psychotic 
disorder and comorbid SUD; (b) participants diagnosed according to DSM or ICD criteria; (c) 
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interventions offered in outpatient settings; (d) a comparison between treatment interventions 
with primary treatment outcome measures; and (e) interventions delivered by a trained 
professional according to existing protocols. Finally, since the vast majority of articles report 
on samples with a variety of severe mental illnesses (e.g. schizophrenia, bipolar disorder) 
and SUD, we additionally limited the selection to articles of which the sample included a 
sizeable (at least 1/3 of patients) proportion of patients with schizophrenia or a psychotic 
disorder. Other patients’ diagnoses were severe mental illnesses such as bipolar disorders or 
other severe affective disorders. 
 
2.2. Statistical analysis 
Treatment effect sizes (Cohen’s d) of the primary outcome measures were retrieved from the 
articles or were calculated according to Thalheimer and Cook [18]. Effect sizes (expressed in 
Cohen’s d) vary from small (up to .20) to medium (from .21 to .79) or large (.80 and above).  
 
3. Results 
3.1. Literature search 
Our search retrieved 119 titles that were further consulted. Of these, 14 were selected for 
review according to the above mentioned selection criteria and can be classified in 4 
categories: first, a total of 3 RCTs investigated the effect of a single intervention compared to 
a standardized alternative. Second, 4 RCTs investigated the effect of adding a set of 
interventions to TAU. Third, another 4 RCTs included ACT. Finally, 3 RCTs involved 
programs that were designed specifically for DD patients. The subsequent paragraphs 
discuss these 14 RCTs according to the 4 categories. The study details and effect sizes of 
the primary outcome measures are reported in Tables 1 to 4. 
 
3.2. RCTs implementing a single intervention 
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In a pilot study by Graeber et al. [19] MI was associated with a reduction in drinking days and 
positive outcomes in terms of abstinence compared to psycho-education (PE; see Table 1). 
The authors concluded that MI was a usefull intervention in patients with schizophrenia and 
comorbid SUD, with an effect size in the same range as found in non-DD SUD patients [19, 
20]. Unfortunately, no outcomes were reported on schizophrenic symptom reduction. In 
contrast to the other studies, this was the only study that included solely alcohol abusing 
SUD patients. 
Ries et al. [21] observed that CoM had a positive effect on treatment outcomes 
regarding substance use and money management compared to non-CoM (non-contingent 
management of monetary benefits; see Table 1). The small sample size and the lack of 
registration of psychiatric outcomes and follow-up (FU) data suggest that replication is 
needed to ascertain whether the effects on SUD are long-lasting and whether psychiatric 
pathology is affected by CoM. The effect size in terms of money management is large, which 
makes it important to investigate whether these effects are long-lasting and how they impact 
the patient’s financial situation and quality of life. 
Martino et al. [22] investigated MI compared to a standard psychiatric interview (SI) 
and found significantly improved treatment outcome in the MI group for SUD patients with 
cocaine as their primary drug (see Table 1). In contrast, SUD patients with cannabis as their 
primary drug reported significantly more benefits from SI, an unexpected finding since these 
patients reported less motivation to change at baseline and were thus expected to benefit 
more from MI. However, these patients had more legal involvements (i.e., were on probation) 
and the authors assume that the contradicting results could be a consequence of external 
pressure to alter drug use. 
In summary, MI was found to be more effective than PE, but it was not consistently 
better than SI in terms of substance use outcome [19, 22]. This inconsistency may reflect a 
difference between subgroups of DD patients. MI seems to be effective in patients with an 
alcohol or cocaine use disorder but not in patients with a cannabis use disorder. CoM was 
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also found to be effective but nothing is known about its long-term outcome in DD-patients 
[21]. 
 
 
[Insert table 1 about here] 
 
 
3.3. RCTs adding a standardized set of interventions to TAU  
Barrowclough et al. [23] reported that adding MI, individual CBT, and FI to TAU was 
associated with a significantly reduced risk of relapse, an improvement in positive symptoms, 
and improved global functioning compared to TAU alone (see Table 2). The date were re-
analyzed at 18 months FU and reported that the difference between treatment conditions 
remained statistically significant regarding global functioning, but that the difference in 
substance use (i.e., relapse rate) was not significant anymore (see Table 2) [24]. 
Furthermore, patients that received the standardized set of interventions had improved 
outcome in terms of negative symptoms at 18 months FU but not immediately after 
treatment. According to the authors, caregivers may have learned to adequately support the 
patients by FI and continued doing so after treatment, hereby improving functioning and 
reducing negative symptoms. Barrowclough and colleagues replicated this study with a much 
larger sample size, but without FI [25]. Relapse rate, psychotic symptoms, functioning, and 
self-harm were similar between treatment conditions (see Table 2). There was, however, a 
significant positive effect of the added interventions regarding abstinence (a secondary 
outcome measure). The authors suggest that a longer duration of treatment could possibly 
lead to better outcomes. However, other studies described in this review report positive 
treatment outcomes with even shorter duration of treatment than the Barrowclough study [19, 
22, 26]. The differences in outcome between the studies of the Barrowclough group may 
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suggest that FI was important in improving psychiatric and functioning outcomes, since all 
other interventions were alike.  
James et al. [27] compared a DD program consisting of stage-wise intervention, MI, 
peer support, PE, harm minimization and RP, with PE alone and found less hospitalizations 
at FU in patients in the DD program compared to PE alone (see table 2). The different 
outcome measures of substance use and psychiatric symptoms were inconsistent. When 
considering primary SUD outcome measures, a reduction in drug abuse was observed in the 
DD program compared to PE but no differences were found for psychological dependence or 
alcohol abuse. Moreover, the primary psychiatric outcome measures indicated that there was 
a reduction in psychiatric symptoms following the DD program compared to PE alone but not 
in the severity of the illness. These inconsistencies may be associated with the duration of 
the DD program, which was considerably shorter than most other studies in this review (6 
weeks compared to often 9 months or more).  
In summary, adding a standardized set of interventions had mixed effects without 
consistent outcomes. Furthermore, the selection of outcomes measures seems to be crucial 
to capture improvement in outcomes. It is interesting to note that 3 out of 4 studies are 
conducted by the same research group and that the outcomes of these 3 studies were 
incidentally very divers. 
 
 
[Insert Tabel 2 about here] 
 
 
3.4. RCTs implementing (integrated) ACT  
Drake et al. [10] and Essock et al. [28] did not find differences in treatment outcomes 
between integrated ACT-model and integrated CM (see Table 3). Apart from caseload and 
thus how many services they offer directly, ACT and CM were approximately equal in 
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content, suggesting that a lower caseload per staff seems not to be associated with better 
outcomes. 
Morse et al. [29] compared integrated ACT (i.e., staff trained in integrated treatment 
principles and services, having a substance use specialist as a team member, and SUD 
focused treatment) with standard ACT and with standard outpatient treatment. Outcomes of 
the two ACT modalities did not differ from one another but the two differed significantly from 
TAU in terms of housing conditions (see Table 3). The absence of difference in treatment 
outcomes between the ACT models could be explained by the great similarities in content 
and the lack of treatment fidelity (i.e., deviation from the proposed manual; e.g., standard 
ACT also provided patients with SUD focused treatment). 
Petersen et al. [6] observed that a modified ACT model including SUD treatment, 
extended family PE, social skills training, and caseload 1:10 was associated with significantly 
better outcomes than standard treatment (consisting of family PE and  caseload 1:20 to 1:30) 
in terms of psychiatric symptoms, number of days in the hospital, and number of patients 
fulfilling SUD criteria at FU. The effect sizes are nevertheless modest (see Table 3). Enriched 
ACT had better outcomes in terms of patients’ treatment adherence than TAU, which was 
reflected in a significantly smaller number of patients without outpatient visits. Petersen et al. 
furthermore observed that there was a lower rate of participation at FU among patients 
without an interview with relatives at baseline, concluding that FI can have a positive impact 
on retention. 
In summary, ACT was not associated with better outcomes than CM, probably due to 
the model’s similar contents. Lower caseload does not seem associated with better outcome. 
ACT provided better treatment outcomes than TAU. Although small in effect sizes, DD 
patients seem to benefit from FI in terms of treatment adherence. 
 
 
[Insert table 3 about here] 
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3.5. RCTs comparing IT programs 
Burnam et al. [30] compared outpatient IT (consisting of group interventions, self-help, 
individual consultations and CM) with identical treatment offered residentially and with a 
control condition (no intervention). Remarkably, the authors did not find any clinically relevant 
differences between these 3 conditions (see Table 4) although they report sufficient power. 
However, effective interventions that are often implemented in other DD programs were not 
implemented in this IT program. This suggests that interventions such as MI or FI are 
necessary for positive outcomes. An interesting FU study would be to compare the program 
in combination with other interventions (e.g., MI, FI or a combination of both interventions) to 
the original program.  
Bellack et al. [26] observed that patients in Behavioral Treatment for Substance 
Abuse in Severe and Persistent Mental Illness (BTSAS; a combination of social skills 
training, MI, PE, RP and CoM) achieved significantly better outcomes in terms of abstinence 
from substance use (reported as drug-free urine samples) and of percentage of patients with 
at least one 4- or 8-week block of continuous abstinence than patients in Supportive 
Treatment for Addiction Recovery (STAR; PE and supportive group therapy) (see Table 4). 
Also, BTSAS was associated with significantly improved attendance and retention. Additional 
exploratory analyses indicated that the number of inpatient admissions and arrests 
significantly decreased and that social functioning, quality of life, life satisfaction, and 
financial situation significantly improved in patients in BTSAS compared to patients in STAR. 
BTSAS indeed seems very promising but only short term effects were found. 
Mueser et al.  [31] compared a Family Intervention for DD (FIDD; comprising of PE, 
skills training, stage-wise intervention and single and multiple family groups) with a family PE 
(FPE) program. FIDD was associated with better outcomes for patients in terms of general 
functioning, overall psychiatric symptoms, and psychotic symptoms revealing small effect 
sizes (see Table 4). Furthermore, mental health and knowledge of DD improved significantly 
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in family members receiving FIDD compared to FPE. This could, in turn, improve patient 
outcomes, since a more stable and well informed family environment can help preventing 
relapse and improving quality of life [32]. Both programs, FPE and FIDD, improved 
psychiatric, substance use, psychosocial, and family functioning outcomes but FIDD 
improved psychiatric outcomes and functioning significantly more than FPE. 
The content of the three IT programs obviously is very divers and makes a general 
conclusion about the efficacy of IT difficult. BTSAS was effective [26], while the Burnam 
program was not [30]. A program that includes family members’ involvement was associated 
with positive treatment outcomes anyhow [31].  
 
 
[Insert table 4 about here] 
 
 
 
4. Discussion 
This review provides an overview of the efficacy of outpatient care for patients with 
schizophrenia and comorbid SUD. Most of the interventions and IT models show beneficial 
effects over TAU but the effect sizes vary substantially. 
The first question is whether a broader set of interventions is related to significantly 
better treatment outcome compared to a limited set of interventions. We identified three 
RCTs implementing a single intervention [19, 21, 22], four using a more extensive set of 
interventions [23-25,27] and three using a fully integrated set of interventions [26, 30, 31]. 
Improved substance use outcomes were observed in two out of three studies including only 
one intervention (MI or CoM) [19, 21]. This is in accordance with two other studies on patient 
populations that did not fulfill inclusion criteria, which also found positive effects of CoM on 
SUD [33, 34]. In terms of psychiatric symptoms, Martino et al. [22] reported that MI improved 
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negative symptoms, but results in terms of various SUD outcomes were inconsistent in this 
study. Adding a single intervention, particularly CoM, is associated with better SUD outcome. 
When offering a combination of interventions, one out of four studies showed 
improvements in both substance use and psychiatric symptoms [27]. Two other studies 
reported discrepant results of their program at 12 and 18 months FU [23, 24]: the effect on 
SUD improvement diminished over time, while a significant effect on psychiatric outcomes 
was found at 18-months FU and improvement of global functioning remained. However, by 
far the largest study only found minor improvements in SUD outcomes [25].  
Finally, one out of four studies on a fully integrated program found improvements on 
psychiatric symptomatology (with a small effect size) [31] and one other study (that 
unfortunately did not assess psychiatric outcomes) observed large effects in terms of SUD at 
the end of treatment [26], in contrast to another study that found no evidence for the efficacy 
of IT [30].  
Despite a large variability in outcome and its measurement, one may conclude that 
more elaborated programs are more positively related to a broader spectrum of improvement 
(i.e., SUD, psychiatric, and/or functioning outcomes) compared to more limited interventions. 
In addition, some studies suggest that intensity and program duration could play an important 
role in achieving better outcomes (e.g., James et al. [27]). These factors should be 
investigated further.  
ACT or CM is often suggested to be an essential part of treatment for SUD patients. 
In this review, we could identify four studies comparing ACT with other interventions [6, 10, 
28, 29]. When a program with ACT was compared to a program without ACT or CM, results 
were inconsistent: one study demonstrated better outcomes of ACT on both SUD and 
psychiatric outcomes [6], whereas another study found very little difference between ACT 
and TAU outcomes (i.e., only in terms of stable housing) [29]. The authors of an excluded 
study concluded that ACT significantly improved quality of life compared to TAU but that 
outcomes of ACT appeared similar to outcomes of an intervention based on group therapy 
[35]. Another study that also did not fulfill inclusion criteria revealed that ACT outperformed 
 14 
an intervention focused on self-help meetings in terms of psychiatric outcomes, family 
interaction and global life satisfaction but SUD was not affected [36]. Overall, ACT programs 
do not seem to be associated with better outcomes than CM [10, 29]. Moreover, CM and 
ACT programs are very similar in content with the exception of their caseload. Also, 
integrated ACT compared to standard ACT did not result in better treatment outcomes [29]. 
Finally, McHugo et al. [11] reanalyzed the data of Drake et al. [10] and showed that patients 
receiving an ACT program implemented with high treatment model fidelity had significantly 
superior outcomes in terms of days of alcohol and drug use, stage of substance abuse 
treatment, percentage of patients with stable remission, and hospital admissions compared 
to patients in programs implemented with low treatment model fidelity. In conclusion, both 
ACT and CM seem effective. The lack of difference indicates that lower patient-staff ratio 
was not associated with better outcomes. Furthermore, high treatment model fidelity is 
important for improvement.  
Given the wide variety and combinations of interventions, it remains difficult to assess 
the effectiveness of each single intervention. All described interventions implemented in IT 
programs are known to be effective in the treatment of (non-DD) SUD patients, but 
effectiveness in DD patients needs to be confirmed. A large number of included studies  
(n=7; [19, 22-26, 28]) implemented MI, and most of these studies reported that the 
experimental condition had significantly better treatment outcomes (mostly in terms of SUD). 
Another frequently implemented intervention was FI (n=5; [6, 23, 24, 28, 31]). Although the 
content of these interventions varied greatly, the outcomes mostly seemed positive. FI 
seems especially promising in terms of ameliorating real-life functioning. Some evidence was 
found for the efficacy of stagewise interventions [28, 31], but one other study (with ACT) did 
not find improved treatment outcomes [10]. Finally, few studies implement RP [26, 27] and 
CoM [21 ,26], but these studies do show very encouraging results. To affirm the impact and 
efficacy of a single intervention to treatment outcomes, one should investigate a combined 
program compared to the program with a single intervention withheld. 
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On of the major strengths of our review consists of the strict selection of RCTs with 
the consequence that informative studies were excluded because they did not meet our 
selection criteria. Of importance, the outcomes of these excluded studies were consistent 
with our results, providing support for our findings. Several limitations warrant careful 
interpretation of our results. Most of these limitations are well known caveats when studying 
the outcome of, complex, real-world, multidisciplinary psychosocial interventional programs. 
First most studies included patients with a psychotic disorder combined with patients with 
other severe mental disorders (mostly bipolar disorders). If we had strictly excluded studies 
with diagnostically mixed samples, only 8 studies would have been selected for review (i.e., 
[6, 19, 22-25, 27, 28]). To our opinion, excluding a large number of patients with 
schizophrenia would be a serious bias in the results. Thus, we believe that including studies 
with mixed samples with a sizeable portion of patients with schizophrenia (at least 1/3) is a 
justifiable decision when the interpretation of the results is carefully done due to samples’ 
heterogeneity. However, DD patients with other severe mental illnesses might need slightly 
different integrated interventions or programs than DD patients with schizophrenia. Secondly, 
two studies included inpatients as well as outpatients [19, 22] and it was not possible to 
dismantle the setting effect in these studies. Thirdly, it was not always possible to elaborate 
on the required intensity of a program due to lack of information or because treatment 
programs provided unlimited care. Fourthly, we found a large variability between studies as 
to the types of interventions offered (and also within the content of the specific interventions), 
the outcome variables used, and the TAU conditions. Finally, we focused on outpatient 
programs, a choice we believe is justified given the present and future relevance of and 
focus on community based service provision [16, 17]. We did not include studies on 
residential programs [37-42], so that results cannot be transferred to inpatient services. The 
outcomes of two of these RCTs on inpatient treatment were consistent with the results of this 
review [39, 40].  
Taken together and in spite of the above mentioned limitation we do think the mayor strength 
of our study is its comprehensiveness, reflective of the current outcome research on dual 
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diagnosis patients in real-world patient samples. Our findings clearly highlight the enormous 
diversity within the clinical and research field both as to the differences of the patient 
samples included as to the different treatment interventions offered in these dual disorder 
programs. This manifest heterogeneity leads us to conclude that future research should 
focus on narrowing patient’s characteristics (e.g., patients with “pure” schizophrenia, poly 
versus single substance use) and tailoring specific interventions or programs related to their 
expected outcomes (i.e., type of substance abused). In addition, one should try to assess 
which specific interventions most strongly drive the positive effects of the treatment. This 
could be done by taking an elaborate program and comparing it with and without each 
intervention. Furthermore, patient (and family) treatment satisfaction needs to be 
incorporated as relevant outcome factors in clinical decision-making. 
We conclude that IT, in particular BTSAS and FIDD, is effective in treating DD 
patients with schizophrenia and SUD. However this conclusion should be taken carefully as 
only 1 study investigated these 2 programs. Additionally, the current evidence supports the 
use of MI, CoM, FI, and RP or a combination of the foregoing in IT programs. Finally, both 
ACT and CM seem similarly effective, suggesting that a lower caseload did not promote 
better outcome. Although our review revealed useful insights in the efficacy of outpatient DD 
treatment, the low number of included studies clearly illustrates the need for additional high 
quality research.  
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Tables 
Table 1  
Overview of the selected randomized controlled trials on the addition of a single intervention to standard treatment in patients with 
schizophrenia and comorbid substance use disorders and their outcomes.  
      Outcomes 
Study Intervention Sample Primary drug 
use 
Duration of the 
intervention (intensity) 
FU Reduction in 
substance use (ES) 
Reduction in psychiatric 
symptom severity (ES) 
Other (ES) 
Graeber et al. 
[19]A 
MI vs. PE n =15 vs.  n 
= 15  
 
Alcohol 3 weeks (1 h/week) 
 
 
24 
weeks  
Lost to 
FU:  
7% 
MI > PE (1.29) Unknown Unknown 
Ries et al. 
[21] 
CoM vs. non-
CoM 
n = 22 vs. n 
= 19  
Various 27 weeks (variable) 
 
None Alcohol: CoM > CM 
(0.87) 
Drugs: CoM > CM 
(0.74) 
Unknown Money management: CoM 
> CM (1.41) 
Martino et al. 
[22] A 
MI vs. SI n = 24 vs. n 
= 20  
Various 1 week (2 x 1h/week)  12 
weeks 
Lost to 
FU: 
23% 
Cocaine: MI > SI (0.5) 
Marijuana: MI < SI 
(1.11) 
PANSS negative: MI < SI (B) Medication and treatment  
adherence:  
MI = SI 
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Notes. The effect sizes (ES) are presented between brackets in the last 3 columns, representing the following magnitude of the effect: small (≤.20), medium 
(>.20 and <.80), large (≥.80). MI: motivational interviewing, PE: psycho-education, FU: follow-up, CoM: contingency management, SI: standard psychiatric 
interview, PANSS: Positive and Negative Syndrome Scale. A This study included inpatients as well as outpatients. B Could not be calculated. 
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Table 2  
Overview of the selected randomized controlled trials adding a standardized set of interventions to treatment as usual in patients with 
schizophrenia and comorbid substance use disorders and their outcomes. 
      Outcomes 
Study Added set of 
interventions (SoI) 
Sample Primary 
drug use 
Duration of the 
intervention (intensity) 
FU Reduction in substance 
use (ES) 
Reduction in psychiatric 
symptom severity (ES) 
Other (ES) 
Barrowclough et al. 
[23] A 
MI + CBT + FI n = 18  
vs. n = 
18  
Various 9 months (variable) 12 months 
Lost to FU: 
13% 
SoI > TAU (B) PANSS positive: SoI > TAU 
(1) 
GAF: SoI > TAU 
(1.42) 
 
Haddock et al. [24] 
A 
MI + CBT + FI n = 18  
vs. n = 
18  
Various 9 months (variable) 18 months 
Lost to FU: 
22% 
SoI = TAU PANSS negative: 
SoI > TAU (1,21) 
GAF: SoI > TAU 
(0.81) 
 
James et al. [27]  MI + PS + RP + PE n = 32  
vs. n = 
31  
Various 6 weeks  
(1 - 1.5 h/week) 
3 months 
Lost to FU: 
8% 
DAST: SoI > TAU (1.09) 
AUDIT and SDS:  
SoI = TAU  
BPRS: SoI > TAU (0.73) 
GSI: SoI = TAU 
Hospitalization:  
SoI < TAU 
(unknown) 
Barrowclough et al. 
[25] 
MI + CBT n = 164  
vs. n = 
163  
Various 12 months (variable) 
 
24 months 
Lost to FU: 
25% 
SoI = TAU 
 
SoI = TAU Hospitalization: 
SoI = TAU 
Notes. The effect sizes (ES) are presented between brackets in the last 3 columns, representing the following magnitude of the effect: small (≤.20), medium 
(>.20 and <.80), large (≥.80). SoI: set of interventions, MI: motivational interviewing, CBT: cognitive behavioral therapy, FI: family and caretaker interventions, 
TAU: treatment as usual, FU: follow-up, PANSS: Positive and Negative Syndrome Scale, GAF: Global Assessment of Functioning Scale, PS: peer support, 
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RP: relapse prevention, PE: psycho-education, DAST: Drug Abuse Screening Test, AUDIT: Alcohol Use Disorder Identiﬁcation Test, SDS: Severity of 
Dependence Scale, BPRS: Brief Psychiatric Rating Scale, GSI: Global Severity Index.  
A These trials report on the same patient sample. B Could not be calculated 
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Table 3  
Overview of the selected randomized controlled trials implementing assertive community treatment in patients with schizophrenia and comorbid 
substance use disorders and their outcomes. 
      Outcomes 
Study Intervention Sample Primary drug 
use 
Duration of the 
intervention 
FU Reduction in 
substance use (ES) 
Reduction in psychiatric 
symptom severity (ES) 
Other (ES) 
Drake et al. 
[10] 
I-ACT vs. I-CM  n = 105 vs. n = 98  Various Unlimited 
 
3 years  
Lost to FU: 
15% 
I- ACT > I-CM (0.19) BPRS: I-ACT = I-CM Stable housing: 
I-ACT = I-CM 
Essock et al. 
[28] 
I-ACT vs. I-CM n = 99 vs. n = 99 Various Unlimited 
 
 
3 years  
Lost to FU: 
10% 
I-ACT = I-CM BPRS: I-ACT = I-CM Stable housing:  
I-ACT = I-CM 
Morse et al. 
[29] 
I-ACT vs. ACT  
vs. SC 
n = 46 vs. n = 54 
vs. n = 49   
Various Unlimited 
 
24 months 
Lost to FU: 
12% 
I-ACT = ACT = SC BPRS: I-ACT = ACT = SC Stable housing:  
I-ACT + ACT > SC 
(0.34) 
I-ACT = ACT 
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      Outcomes 
Study Intervention Sample Primary drug 
use 
Duration of the 
intervention 
FU Reduction in 
substance use (ES) 
Reduction in psychiatric 
symptom severity (ES) 
Other (ES) 
Petersen et 
al. [6] 
Enriched  ACT vs. 
TAU 
n = 74 vs. n = 74  Various Unlimited 2 years 
Lost to FU: 
44% 
ACT > TAU (A) Positive symptoms: 
ACT = TAU 
Negative symptoms: ACT > 
TAU (0.43) 
Disorganized symptoms:  
ACT > TAU (0.20) 
Hospitalization:  
ACT < TAU (0.32) 
Notes. The effect sizes (ES) are presented between brackets in the last 3 columns, representing the following magnitude of the effect: small (≤.20), medium 
(>.20 and <.80), large (≥.80). I-ACT: integrated assertive community treatment, I-CM: integrated case management, FU: follow-up, BPRS: Brief Psychiatric 
Rating Scale, SC: standard care, ACT: assertive community treatment, TAU: treatment as usual. 
A Could not be calculated 
 
  
 28 
Table 4 
Overview of the selected randomized controlled trials comparing integrated treatment programs in patients with schizophrenia and comorbid 
substance use disorders and their primary outcomes. 
      Outcomes 
Study Intervention Sample Primary drug use Duration of the 
intervention (intensity) 
FU Reduction in 
substance use (ES) 
Reduction in psychiatric 
symptoms (ES) 
Other (ES) 
Burnam et 
al. [30] 
RIT vs. AIT  
vs. no 
intervention 
n = 67 vs. n 
= 144 
vs. n = 65 
Various 3 months (intensive) +3 
months (optional) 
9 months 
Lost to FU: 
42% 
RIT = AIT  
= no intervention 
RIT = AIT  
= no intervention 
Housing: RIT = AIT  
= no intervention 
Bellack et al. 
[26] 
BTSAS vs. 
STAR 
n = 61 vs. n 
= 49 
Alcohol, cocaine, 
heroin, cannabis 
6 months  
(2x / week)  
End of 
treatment 
Lost to FU: 
25% 
BTSAS > STAR 
(0.76) 
Unknown Attendance: BTSAS > 
STAR (0.64) 
  
Mueser et 
al. [31] 
FIDD vs. FPE n = 52 vs. n 
= 56 
Various FIDD: 9 – 18 months (20 
– 30 sessions)  
FPE: 2 – 3 months 
(6-8x 1h/week) 
36 months 
Lost to FU: 
55% 
FIDD = FPE BPRS total: 
FIDD > FPE (0.17) 
BPRS psychoses: 
FIDD > FPE (0.32) 
GAS: FIDD > FPE 
Notes. The effect sizes (ES) are presented between brackets in the last 3 columns, representing the following magnitude of the effect: small (≤.20), medium 
(>.20 and <.80), large (≥.80). RIT: residential integrated treatment, AIT: ambulatory integrated treatment, FU: follow-up, BTSAS: Behavioral Treatment for 
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Substance Abuse in Severe and Persistent Mental Illness, STAR: Supportive Treatment for Addiction Recovery, FIDD: Family intervention for dual diagnosis, 
FPE: family psycho-educational program, BPRS: Brief Psychiatric Rating Scale, GAS: Global Assessment Scale. 
